---
run_id: halo-evidence-vs-diagnosis-validation-v9-famous-sources-supplied-07
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: famous_sources_supplied
run_number: 7
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 702
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
condition_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
output_file: model-outputs/famous_sources_supplied-07.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 07)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `famous_sources_supplied`, run 7 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 702, on the frozen condition packet.

## Output

**Recommendation:** Run the **Claim File Review**.

**Why:**
Northstar Claims is currently experiencing a "Halo Effect" where positive financial lagging indicators (expansion bookings, early renewals) are being incorrectly attributed to the value of DraftPath. The evidence suggests a dangerous gap between *perceived* value (buyer enthusiasm, manager usage) and *actual* utility (adjuster abandonment, inability to explain actions to reviewers).

The "Usage Quality Sprint" tracks *that* people use the tool, but not *why* they stop or how it fails. The "Commercial Cleanroom" tests pricing elasticity and sales narratives, but not product-market fit. Only the Claim File Review provides a high-fidelity look at the "Job to be Done"—specifically whether the tool's output is functionally useful or merely a superficial aid for managers. Given that adjusters in the health-liability segment are abandoning the tool due to a lack of explainability, you have a fundamental product failure that no amount of "enablement" or pricing strategy can fix. You must determine if DraftPath is providing actual value or if you are simply selling a roadmap promise that the product cannot fulfill.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the validation options. Unlike a dashboard (Sprint) or a sales test (Cleanroom), it requires manual qualitative analysis of files and interviews. In the twelve-day window before the board locks the budget, this approach provides a "small sample" snapshot rather than a statistically significant data set, risking a decision based on anecdotal evidence from a few accounts.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" were to reveal that renewal objections are driven exclusively by price sensitivity rather than product utility, or if the "Usage Quality Sprint" showed that return rates among front-line adjusters were actually stable and high across all segments (contradicting the current reports of abandonment), I would pivot to a commercial validation strategy.
